Inquiry Basket
Loading ......
Filter By Product Search for
M. pneumoniae
M. pneumoniae Full Name
Mycoplasma pneumoniae
M. pneumoniae Introduction
Mycoplasma pneumoniae is a cell wall-deficient bacterium belonging to the class Mollicutes that represents one of the most common causes of community-acquired respiratory tract infections, particularly in children, adolescents, and young adults. This organism possesses the smallest genome of any free-living organism capable of self-replication (approximately 816 kb), reflecting extensive evolutionary genome reduction and dependence on host-derived nutrients. The absence of a cell wall distinguishes mycoplasmas from typical bacteria and has important implications for diagnosis, treatment, and pathogenesis: mycoplasmas are inherently resistant to beta-lactam antibiotics that target cell wall synthesis, they cannot be visualized by Gram staining, and they exhibit pleomorphic morphology ranging from coccoid to filamentous forms. M. pneumoniae causes a spectrum of respiratory illnesses ranging from mild upper respiratory tract infections (pharyngitis, tracheobronchitis) to atypical pneumonia, often referred to as "walking pneumonia" due to its typically gradual onset and ambulatory presentation that allows patients to continue daily activities despite infection. Epidemiological patterns demonstrate cyclical outbreaks occurring every 3-7 years in communities, with peak incidence in school-aged children (5-15 years) and young adults, although all age groups can be affected.
The pathogenesis of M. pneumoniae infection involves attachment to respiratory epithelial cells via specialized tip structures containing the P1 adhesin protein, followed by induction of ciliary dysfunction, epithelial damage, and inflammatory responses. The P1 adhesin (170 kDa) is concentrated at the terminal organelle, a polar structure that mediates gliding motility and high-affinity binding to sialylated glycoprotein receptors on host cells. Following attachment, M. pneumoniae induces ciliostasis, loss of ciliated epithelial cells, and recruitment of inflammatory cells including lymphocytes and macrophages, resulting in peribronchial and perivascular infiltrates characteristic of mycoplasmal pneumonia. Unlike typical bacterial pneumonia with alveolar consolidation, M. pneumoniae infection produces an interstitial inflammatory pattern visible on chest radiography as reticulonodular or patchy infiltrates. Extrapulmonary manifestations occur in 10-25% of patients and may involve virtually any organ system, including neurological complications (encephalitis, transverse myelitis, Guillain-Barré syndrome), dermatological manifestations (Stevens-Johnson syndrome, erythema multiforme), cardiac involvement (myocarditis, pericarditis), and hematological abnormalities (hemolytic anemia associated with cold agglutinins). These extrapulmonary manifestations may result from direct invasion, immune-mediated mechanisms, or vascular occlusion, and can occur during or after respiratory illness.
Diagnosis of M. pneumoniae infection has evolved from culture-based methods and serology to molecular techniques that offer improved sensitivity and rapid turnaround times. Culture of M. pneumoniae requires specialized media (SP4, Hayflick) and prolonged incubation (2-6 weeks), making it impractical for routine clinical diagnosis. Serological methods including complement fixation, enzyme immunoassays, and particle agglutination detect antibodies to M. pneumoniae antigens, but require paired acute and convalescent sera for definitive diagnosis and may cross-react with other mycoplasmas. Cold agglutinins (IgM antibodies that agglutinate erythrocytes at 4°C) are present in approximately 50% of M. pneumoniae pneumonia cases but are non-specific. Nucleic acid amplification tests (NAATs), particularly real-time PCR targeting the P1 adhesin gene or 16S rRNA, have become the preferred diagnostic method, offering high sensitivity and specificity with results available within hours. Treatment of M. pneumoniae infection involves macrolides (azithromycin, clarithromycin), fluoroquinolones (levofloxacin, moxifloxacin), or tetracyclines (doxycycline), as beta-lactam antibiotics are ineffective against cell wall-deficient organisms. The emergence of macrolide-resistant M. pneumoniae strains, particularly prevalent in Asia (>90% in some regions) but increasingly reported worldwide, has complicated empirical treatment approaches and underscores the importance of surveillance and antimicrobial stewardship.
Alternate Names for M. pneumoniae
bacterial pneumonia; M. pneumonia; Firmicutes; Mollicutes; Mycoplasmatales; Mycoplasmataceae; Mycoplasma; Mycoplasma pneumoniae;
Loading ......
